Ingenix has successfully secured €13 million in funding to advance its innovative Biological Reasoning Engine, which utilizes a novel AI architecture called Modality Fusion for drug development.
This funding round, led by Sofinnova Partners with additional contributions from Inovo VC and OTB VC, aims to enhance Ingenix's collaborations with pharmaceutical and biotech companies through its newly launched Qualified Access Program. The Biological Reasoning Engine has demonstrated impressive capabilities, completing in minutes what traditionally took years of research and substantial financial investment.
Ingenix's approach addresses the complexities of biological data integration, which conventional AI models struggle to handle. By combining various data modalities and biological scales, Modality Fusion enables the Engine to reason directly across these representations. This methodology allows for more nuanced insights into drug development, particularly in areas such as oncology, where Ingenix recently identified promising dual-payload antibody-drug conjugate (ADC) candidates from a vast pool of possibilities.
The success of Ingenix's Biological Reasoning Engine underscores the potential of specialized AI architectures in life sciences, moving beyond generic models to solutions that are tailored for the intricacies of biological data. As the company expands its partnerships, the implications for accelerated drug development and enhanced research capabilities could be significant, potentially reshaping how the industry approaches complex biological challenges.